Currently, pan-targeted anti-angiogenic tyrosine kinase inhibitors (TKIs) targeting EGFR mainly act on the extracellular domain of EGFR, blocking intracellular signaling pathways such as MAPK and PI3K in tumor cells to control tumor growth, which is the direction of anti-EGFR treatment for gliomas. The gene discussed is EGFR; the disease is glioma.